Requested retraction of six studies on the PK/PD and tolerability of fospropofol

European Journal of Anaesthesiology

Volumn 27, Issue 4, 2010, Pages 395-

  Struys, Michel M R F ^a,b   Fechner, Jörg ^c   Schüttler, Jürgen ^c   Schwilden, Helmut ^c  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FOSPROPOFOL; PROPOFOL; INTRAVENOUS ANESTHETIC AGENT;

ASSAY; BELGIUM; CHEMICAL ANALYSIS; DRUG INDUSTRY; DRUG SCREENING; DRUG TOLERABILITY; GERMANY; LETTER; METHODOLOGY; PUBLISHING; ANALOGS AND DERIVATIVES; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); TIME;

ANESTHETICS, INTRAVENOUS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; PROPOFOL; RETRACTION OF PUBLICATION AS TOPIC; TIME FACTORS;

EID: 77953781742     PISSN: 02650215     EISSN: 13652346     Source Type: Journal    
DOI: 10.1097/EJA.0b013e3283382014     Document Type: Letter

References (9)

1. Shah A, Mistry B, Gibiansky E, Gibiansky L. Fospropofol assay issues and impact on pharmacokinetic and pharmacodynamic evaluation. Anesthesiology 2008; 109:937; discussion.
2. Shah A, Mistry B, Gibiansky E, Gibiansky L. Fospropofol assay issues and impact on pharmacokinetic and pharmacodynamic evaluation. Anesth Analg 2009; 108:382.
3. Shah A, Mistry B, Gibiansky E, Gibiansky L. Fospropofol assay issues and impact on pharmacokinetic and pharmacodynamic evaluation. Eur J Anaesthesiol 2009; 26:81.
4. Fechner J, Ihmsen H, Hatterscheid D, Schiessl C, Vornov JJ, Burak E, Schwilden H, Schuttler J. Pharmacokinetics and clinical pharmacodynamics of the new propofol prodrug GPI 15715 in volunteers. Anesthesiology 2003; 99:303-313. (Pubitemid 36909556)
5. Fechner J, Ihmsen H, Hatterscheid D, Jeleazcov C, Schiessl C, Vornov JJ, Schwilden H, Schuttler J. Comparative pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 and propofol emulsion. Anesthesiology 2004; 101:626-639.
6. Fechner J, Ihmsen H, Schiessl C, Jeleazcov C, Vornov JJ, Schwilden H, Schuttler J. Sedation with GPI 15715, a water-soluble prodrug of propofol, using target-controlled infusion in volunteers. Anesth Analg 2005; 100:701-706.
7. Gibiansky E, Struys MMRF, Gibiansky L, Vanluchene AL, Vornov J, Mortier EP, Burak E, Van Burtel L. AQUAVAN Injection, a water-soluble prodrug of propofol as bolus injection: a Phase I dose escalation comparison with DIPRIVAN. Part 1: pharmacokinetics. Anesthesiology 2005; 103:718-729.
8. Struys MMRF, Vanluchene ALG, Gibiansky E, Gibiansky L, Vornov J, Mortier EP, Van Bortel L. AQUAVAN, a water-soluble prodrug of propofol as a bolus injection: A Phase I dose escalation comparison with DIPRIVAN (part 2): pharmacodynamics and safety. Anesthesiology 2005; 103:730-743.
9. Schywalsky M, Ihmsen H, Tzabazis A, Fechner J, Burak E, Voronov J, Schwilden H. Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats. Eur J Anaesthesiol 2003; 20:182-190. (Pubitemid 36286285)